PARGY-LAD (N6-propargyl-6-nor-lysergic acid diethylamide, also known as 6-propargyl-6-nor-LSD) is a synthetic psychedelic of the lysergamide family. It is structurally related to AL-LAD (6-allyl-6-nor-LSD) but features a propargyl group (containing a terminal alkyne) at the N6 position rather than AL-LAD's allyl group (terminal alkene). This structural relationship makes PARGY-LAD the alkyne analog of AL-LAD, with the propargyl group's triple bond geometry producing different steric and electronic properties at the lysergamide receptor binding interface.
PARGY-LAD is one of the rarer and less documented lysergamide research chemicals. Community experience is limited, making characterization of its subjective effects less certain than for better-studied compounds. Available reports describe an experience broadly similar to AL-LAD — shorter duration than LSD (approximately 6–9 hours), visually rich, and somewhat lighter in character than LSD — with the propargyl substitution possibly contributing subtle differences in quality that are difficult to characterize from sparse data. The compound has attracted interest as one of the few truly distinct direct-acting (non-prodrug) lysergamide analogs in the research chemical market.
Given the very limited community knowledge base, extreme caution with initial doses is warranted for PARGY-LAD. Dose-response relationships have not been formally characterized, and extrapolation from AL-LAD or LSD data must be made conservatively. Testing with Ehrlich reagent is essential, and all standard lysergamide contraindications apply.
Safety at a Glance
High Risk- Ehrlich reagent: purple/violet confirms an indole compound. Given PARGY-LAD's rarity and limited supply chain visibil...
- Dosing is highly uncertain given the sparse community knowledge base. Conservative extrapolation from AL-LAD:
- Toxicity: Acute Toxicity No formal toxicological data exist for PARGY-LAD. By structural analogy to AL-LAD and LSD, acute toxic...
- Overdose risk: Fatal overdose from PARGY-LAD alone, at doses within the typical recreational range, is extremely...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 8 hrsHow It Feels
Information about PARGY-LAD comes from a very small pool of human experience, and what follows reflects the limited reports available. The onset is slow and uncertain, arriving over thirty to sixty minutes with an ambiguous collection of physical signals: a mild tightening in the stomach, a subtle shift in body temperature, and a vague sense that something is changing at the periphery of consciousness.
The physical character is unremarkable but present. There is a moderate body load, neither comfortable nor distressing, that settles primarily in the abdomen and lower back. A mild stimulation keeps the body alert without producing restlessness. The overall physical profile occupies a middle ground, more pronounced than the gentlest lysergamides but far less demanding than ETH-LAD or LSA. Tactile sensitivity increases slightly, and there is a gentle warmth that spreads through the torso.
At whatever passes for peak effect, PARGY-LAD produces a moderate visual enhancement and a mild to moderate cognitive shift. Surfaces may exhibit gentle breathing and flowing patterns, and colors gain some additional saturation. The headspace carries a contemplative quality, a tendency toward reflective thought and emotional openness, but without the intensity or depth that characterizes the more potent members of the family. There is a dreamy, slightly distant quality to the experience, as though the substance is gesturing toward the full lysergamide territory without fully committing to the journey.
The offset is gradual and gentle. Effects taper over several hours, leaving a mild afterglow of slightly enhanced perception and a quiet, reflective mood. The rarity of this substance means that the contours of its experience remain only partially mapped, each report adding detail to a portrait that is still largely sketched in outline. What is clear is that PARGY-LAD occupies a quiet corner of the lysergamide family, offering a moderate and somewhat indistinct psychedelic experience that is more notable for its scarcity than for any single defining characteristic.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(26)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(3)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Perception of self-design— Perception of self-design is the powerful and often paradoxical feeling that one has personally auth...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
PARGY-LAD is believed to act as a direct 5-HT2A receptor partial agonist, not as a prodrug for another compound. The propargyl group at N6 modifies receptor binding geometry and kinetics relative to LSD's N-diethyl substitution or AL-LAD's allyl group. The terminal alkyne geometry of the propargyl group produces a linearly extended, sterically constrained substituent, which may produce faster receptor dissociation kinetics than LSD (potentially contributing to shorter duration) while maintaining sufficient 5-HT2A affinity for psychedelic activity.
Receptor Targets
- 5-HT2A receptors — primary psychedelic target; partial agonist; binding affinity and kinetics modified by N6-propargyl group
- 5-HT1A receptors — likely partial agonist activity; contributes to character of experience
- 5-HT2C receptors — expected affinity; anxiogenic contribution
- Dopamine D2/D3 receptors — moderate affinity expected; contributes to stimulation and mood
- α-adrenergic receptors — sympathomimetic effects
Pharmacokinetics
No formal human pharmacokinetic data exist for PARGY-LAD. Based on structural analogy to AL-LAD, onset is expected at approximately 30–75 minutes. Duration may be shorter than LSD at approximately 6–9 hours. Community reports are too sparse for reliable characterization. No prodrug conversion step is expected; PARGY-LAD should act directly.
Tolerance
Cross-tolerance with LSD and all serotonergic psychedelics is expected. Functional tolerance develops within 24–48 hours.
Detection Methods
Urine Detection
PARGY-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for PARGY-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
PARGY-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for PARGY-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
PARGY-LAD was synthesized as part of the broader systematic exploration of lysergamide structure-activity relationships, building on the work of Alexander and Ann Shulgin documented in TiHKAL and the earlier Sandoz research program. David Nichols and colleagues explored AL-LAD and related N6-substituted nor-LSD derivatives in the 1980s and 1990s, and PARGY-LAD represents an extension of that structure-activity work to the propargyl substituent.
Research Chemical Market
PARGY-LAD appeared in the research chemical market as vendors explored the space of non-prodrug lysergamide analogs. Its relatively low popularity compared to AL-LAD or the 1-acyl LSD series reflects both its obscurity and the more limited documentation of its effects.
Legal Status
PARGY-LAD is not specifically scheduled under international drug conventions but may fall under analog act provisions in the United States and novel psychoactive substance laws in the UK and EU. Legal status varies by jurisdiction.
Harm Reduction
Testing
Ehrlich reagent: purple/violet confirms an indole compound. Given PARGY-LAD's rarity and limited supply chain visibility, testing is especially critical.
Dosing
Dosing is highly uncertain given the sparse community knowledge base. Conservative extrapolation from AL-LAD:
- Threshold: 50–75 μg
- Light: 75–100 μg
- Common: 100–200 μg
- Strong: 200–300 μg
Start at the very low end — 50 μg or below — until individual response is established. The limited community experience means the dose-response relationship has not been well-characterized.
Set and Setting
- Stable emotional state; familiar, comfortable, safe environment
- Trip sitter strongly recommended given the limited knowledge base
- More experienced lysergamide users are better positioned to navigate uncertain dose-response curves
Dangerous Combinations
- Lithium — Contraindicated across the lysergamide class
- MAOIs — Serotonin syndrome risk
- Tramadol — Seizure risk
- Cannabis — Risk of amplified anxiety and disorientation
- Stimulants — Cardiovascular and psychological intensity amplification
Emergency Protocol
- Difficult experience: environment change, grounding, benzodiazepines (diazepam 10–20 mg)
- Emergency services for physical safety concerns
Toxicity & Safety
Acute Toxicity
No formal toxicological data exist for PARGY-LAD. By structural analogy to AL-LAD and LSD, acute toxicity is expected to be very low. No fatalities attributable to PARGY-LAD have been documented.
Cardiovascular Effects
Sympathomimetic effects consistent with the lysergamide class: mild tachycardia, blood pressure elevation, mydriasis. Contraindicated with cardiovascular disease.
Psychological Risks
- Acute anxiety and panic — dose-dependent; more uncertain given sparse experience data
- Psychosis induction — absolute contraindication with history of schizophrenia or bipolar I disorder
- HPPD — risk with any serotonergic psychedelic
Contraindications
Personal or family history of psychosis or bipolar disorder; lithium, MAOI, antipsychotic, or tramadol use; cardiovascular disease.
Overdose
No documented pharmacological overdoses. Benzodiazepines for acute distress.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from PARGY-LAD alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Germany: PARGY-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Latvia: PARGY-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Switzerland: PARGY-LAD is not specifically named under Buchstabe A, B, C and D. It is also not controlled as a defined derivative of Lysergic Acid under Verzeichnis E point 263 due to its alkynyl substitution which is not included. It can be considered legal.
United Kingdom: As of January 7, 2015, PARGY-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
Responsible use (Hallucinogens)
Psychoactive substance index
Research chemical
Hallucinogens
Psychedelic
Lysergamide
LSD
PARGY-LAD (Wikipedia)
PARGY-LAD (Isomer Design)
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.
Experience Reports (1)
Tips (3)
Use a milligram scale to weigh PARGY-LAD if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Always test PARGY-LAD with an Ehrlich reagent before use. A positive reaction (purple/pink color change) confirms the presence of an indole/lysergamide compound. No reaction could indicate a dangerous substitute like an NBOMe.
Clear your schedule for the full duration of PARGY-LAD plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: PARGY-LAD
PubChem compound page for PARGY-LAD (CID: 139030999)
pubchem - PARGY-LAD - TripSit Factsheet
TripSit factsheet for PARGY-LAD
tripsit - PARGY-LAD - Wikipedia
Wikipedia article on PARGY-LAD
wikipedia